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Abstract The pathogenesis of autoantibody-mediated cel-
lular and tissue lesions in autoimmune diseases is most
straightforwardly attributable to the combined action of
self-antigen binding properties and effector functions
associated with the Fc regions of the different immuno-
globulin (Ig) isotypes. The analysis of two different sets of
monoclonal autoantibodies derived from lupus-prone mice
revealed remarkable differences in the pathogenic potentials
of different IgG subclasses: (1) the IgG2a and IgG2b
subclasses of anti-red blood cell (RBC) autoantibodies are
the most pathogenic and efficiently activate two classes of
activating IgG Fc receptors (FcγRIII and FcγRIV) and
complement; (2) the IgG3 subclass is less pathogenic and
activate only complement; and (3) the IgG1 subclass is the
least pathogenic and interact only with FcγRIII. In
addition, because of the unique property of IgG3 to form
self-associating complexes and generate cryoglobulins, this
subclass of rheumatoid factor and anti-DNA autoantibodies
became highly pathogenic and induced lupus-like nephritis
and/or vasculitis. Since the switch to IgG2a and IgG3 is
promoted by Th1 cytokine interferon γ, these results
strongly suggest that Th1 autoimmune responses could be
critically involved in the generation of more pathogenic
autoantibodies in systemic lupus erythematosus. This
finding is consistent with the observation that the progres-
sion of murine lupus nephritis is correlated with the relative
dominance of Th1 autoimmune responses. Finally, the
analysis of IgG glycosylation pattern revealed that more
sialylated IgG autoantibodies remained poorly pathogenic
because of limited Fc-associated effector functions and loss
of cryoglobulin activity. This suggests that the terminal
sialylation of the oligosaccharide side chains of IgG could
be a significant factor determining the pathogenic potential
of autoantibodies. Our results thus underline the importance
of subpopulations of autoantibodies, induced by the help of
Th1 cells, in the pathogenesis of autoantibody-mediated
cellular and tissue injuries.
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Introduction
Autoantibodies are the essential factors for several clinical
manifestations associated with systemic lupus erythemato-
sus (SLE). Because of the occasional lack of correlation
between elevated serum levels of autoantibodies and clinical
manifestations, it has long been suggested that only a subset
of autoantibodies generated during the course of SLE is
indeed pathogenic and that the qualitative aspects of
autoantibodies are important for the pathogenesis of autoan-
tibody-mediated cellular and tissue injuries. Immunoglobulin
(Ig) G autoantibodies such as anti-DNA autoantibodies can
provoke tissue lesions as a result of their deposition as a
form of immune complexes (ICs) in renal glomeruli and
small vessels, resulting in glomerulonephritis and vasculi-
tis. Although it is unique in murine SLE, a major
pathogenic role for autoantibodies to the endogenous
retroviral glycoprotein gp70 has been demonstrated, as
gp70–anti-gp70 ICs become apparent in the circulation
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close to the onset of disease and their concentrations rise
with the progression of lupus nephritis [25]. Cross-
reactivity of anti-DNA antibodies with glomerular autoan-
tigens, such as alpha actinin-4 (a protein within the
glomerular epithelial slit pore complex), and direct reactiv-
ity of a fraction of autoantibodies with glomerular matrix
autoantigens, such as heparin sulfate and laminin, have also
been postulated as mechanisms of immune deposition [10,
41, 44]. The binding of certain autoantibodies such as
antierythrocyte and antiplatelet autoantibodies to their
targets can lead to direct cellular damage, causing hemo-
lytic anemia and thrombocytopenia. Moreover, a separate
group of autoantibodies are directed against phospholipids
complexed to β2-glycoprotein 1 and associated with
thrombotic complications called antiphospholipid syn-
drome, which is a major clinical problem in some lupus
patients [28, 38].
The structure of the Fab region defines the specificity
and affinity with which autoantibodies bind to self-antigen.
In addition, the Fc region plays a critical role in
autoantibody pathogenicity by activating IgG Fc receptor
(FcγR)-bearing effector cells, by activating the complement
cascade, and by inducing IgM multivalency-dependent
agglutination of target cells. Thus, the pathogenic potential
of autoantibodies is attributable to the combined action of
the self-antigen binding properties of the Fab region and the
effector functions associated with the Fc region of the
different Ig isotypes. Therefore, it is conceivable that a
change of IgG subclass can remarkably modify the
pathogenicity of autoantibodies because of alterations in
Fc-dependent effector functions. Notably, the spontaneous
development of murine lupus nephritis is dependent on the
activation of complement [67] and FcγR-bearing effector
cells [8]. Murine immune effector cells express three
different classes of activating FcγRs: the high-affinity
FcγRI, the recently identified intermediate-affinity FcγRIV,
and the low-affinity FcγRIII [46]. These three FcγRs are
hetero-oligomeric complexes in which the respective
ligand-binding α-chains are associated with the common
γ-chain (FcRγ). FcRγ is critical for the cell surface
expression of these three activating receptors and for the
triggering of their various effector functions, including
phagocytosis by macrophages, degranulation by mast cells,
and antibody-dependent cell-mediated cytotoxicity by NK
cells.
In an attempt to better define the importance of certain
subpopulations of autoantibodies in the pathogenesis of
autoantibody-mediated cellular and tissue injuries, we have
assessed the pathogenic activity of two different sets of
autoantibodies: anti-red blood cell (RBC) monoclonal
autoantibodies derived from lupus-prone NZB mice and
anti-IgG2a rheumatoid factors (RFs) derived from lupus-
prone MRL-Faslpr mice. In this review, we discuss the
molecular and cellular basis of the pathogenic activities of
anti-RBC autoantibodies and anti-IgG2a RFs in relation to
the effector functions associated with the Fc region of the
different Ig isotypes. In addition, we also highlight the role
of IgG glycosylation for effector functions and hence
pathogenic potential.
Pathogenicity of anti-RBC monoclonal autoantibodies
The experimental model of autoimmune hemolytic anemia
induced by a single injection of Coombs’ antierythrocyte
autoantibodies derived from autoimmune-prone NZB mice
presents remarkable advantages for the assessment of the
pathogenic activity of autoantibodies. First, the binding of
the anti-RBC autoantibodies in vivo after injection of anti-
RBC autoantibodies into mice can easily be monitored by
flow cytometric analysis of circulating, opsonized RBCs.
Second, the pathogenic effect of the anti-RBC autoanti-
bodies, i.e., the development of anemia, can be followed by
a simple measurement of hematocrit values in mice. Finally,
the pathogenic mechanisms of anemia and its severity can
be determined through histological analysis of spleen and
liver, including evaluation of the extent of erythrophago-
cytosis by hepatic Kupffer cells.
Although the molecular nature of the target autoantigens
responsible for the induction of anti-RBC autoimmune
response has not been well characterized, the analysis of a
panel of anti-RBC monoclonal antibodies (mAb) derived
from NZB mice has shown that the pathogenic autoanti-
bodies (i.e., capable of inducing anemia) recognize only
species-specific antigens on mouse RBCs, whereas non-
pathogenic autoantibodies cross-react with determinants
present on RBCs from many different species [7, 57].
Significantly, comparative analysis between young and
aged RBCs revealed that the expression of the murine
autoantigen implicated in autoimmune hemolytic anemia
progressively increased during the course of RBC aging in
the circulating blood [16]. Aged RBCs were preferentially
eliminated from the circulating blood following the injec-
tion of anti-RBC autoantibodies, despite relatively small
differences of anti-RBC binding to young and aged RBCs
(less than twofold differences). This emphasizes the
biological significance of twofold or even less than twofold
differences in the expression levels of autoantigens on
target cells in the process of antibody-dependent immune
clearance. In marked contrast to the autoimmune determi-
nant, the expression level of the CD44, CD47, CD147, and
TER-119 epitopes, which are recognized by mAb deliber-
ately raised in non-autoimmune animals, rather decreased
or remained unchanged with RBC aging. These data
unravel the unique molecular feature of RBC epitopes
involved in autoimmune hemolytic anemia, suggesting that
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age-dependent alterations in cellular membrane proteins
might have a critical importance in the development of
autoantibody responses to RBCs.
Marked differences in IgG-subclass-dependent
pathogenicity of anti-RBC autoantibodies
In view of differences in Fc-associated effector functions
among the four different IgG subclasses in mice, we have
generated IgG subclass switch variants of a high-affinity
34-3C IgG2a anti-RBC autoantibody derived from NZB
mice. We then determined the differences in the pathogenic
mechanisms between the IgG subclasses by assessing their
respective capacities to induce anemia in vivo in mice
deficient in the common γ-chains of FcγR (i.e., no
functional expression of activating FcγRI, FcγRIII and
FcγRIV) or in C3 [3]. The four IgG subclasses of the
34-3C antibody displayed striking differences in their
pathogenic activities, which depended on the capacity of
the individual IgG subclasses to activate FcγR and/or
complement (Tables 1 and 2). IgG2a and IgG2b, which
both efficiently interacted with FcγRIII and FcγRIV and
activated complement, exhibited the highest pathogenic
activity. They were followed by the IgG3 subclass, which
activated only complement (but was unable to interact with
any FcγR), and then by the IgG1 subclass, interacting only
with FcγRIII but failing to activate complement. Overall,
IgG2a and IgG2b were 20-fold more potent than IgG1.
Role of complement and its inhibitory proteins
Early studies have shown that the development of anemia
with a single dose of 34-3C IgG2a or polyclonal rabbit IgG
antimouse RBC antibodies was not affected in C3-depleted
or C3-deficient mice [57, 58], thus suggesting that
complement played no role in the development of autoim-
mune hemolytic anemia. However, the analysis of IgG
switch variants of the 34-3C mAb with different doses has
provided new insight into this issue (Table 2): complement
activation was indeed involved in the development of
anemia through complement receptor (CR)-mediated eryth-
rophagocytosis in a dose-dependent and IgG-subclass-
specific manner [3]. For example, C3 deficiency only
minimally affected the development of mild anemia at a
low dose (50 μg) of the IgG2a subclass, whereas CR-
dependent erythrophagocytosis significantly contributed to
the development of severe anemia induced by a high dose
(200 μg) of this subclass in normal mice. This indicates that
CR-mediated erythrophagocytosis requires an extensive
opsonization of RBCs by C3 fragments. In contrast, a
limited opsonization with IgG2a antibodies was sufficient
to trigger FcγR-dependent erythrophagocytosis. This is
consistent with the finding that despite a lack of appreciable
opsonization of RBCs, the low-affinity 4C8 IgG2a mAb
was able to induce severe anemia as a result of FcγR-
mediated phagocytosis by Kupffer cells [15]. Notably, the
IgG3 subclass, which fails to interact with phagocytic
FcγR, was able to induce anemia as a result of CR-
mediated erythrophagocytosis. Furthermore, the active
involvement of complement in autoantibody-mediated
autoimmune pathology has also been documented in
experimental models of antiglomerular basement membrane
nephritis [64], antiphospholipid syndrome [21], and auto-
immune vitiligo [65].
It is somehow unexpected that none of the anti-RBC
monoclonal autoantibodies, even of the IgM isotype, was
able to induce complement-mediated hemolysis. Indeed, the
development of anemia after the injection of IgM anti-RBC
autoantibodies at any dose was not prevented in mice
deficient in C3 or C5 [57]. The lack of involvement of
complement-mediated intravascular hemolysis is likely due
to the activity of a number of complement inhibitory
proteins present on RBC membranes. This idea was
supported by the demonstration that 34-3C IgG2a-opson-
ized RBCs deficient in the membrane-bound complement
regulatory proteins Crry (CR1-related gene/protein y) and
DAF (decay accelerating factor) were eliminated more
rapidly by complement-dependent clearance than by the
FcγR-dependent pathway [42]. Although this study did not
directly demonstrate that deficiency in Crry and DAF
results in intravascular hemolysis of 34-3C IgG2a-opson-
ized RBCs, it has been shown that DAF-deficient RBCs
Table 1 Effector functions of 34-3C anti-RBC Ig class switch
variants
Ig FcγRI FcγRIII FcγRIV FcγRIIB C′
IgG2a + ++ ++ + ++
IgG2b − ++ ++ ++ ++
IgG3 − − − − +
IgG1 − + − ++ −
IgM − − − − ++
Table 2 Pathogenic activities of 34-3C anti-RBC Ig class switch
variants and respective contributions of FcγRIII, FcγRIV, and
complement to the development of autoimmune hemolytic anemia
Ig Anemic
dosea
Effector
mechanisms
Pathogenesis
IgG2a 25 μg FcγRIII > FcγRIV, C′ Erythrophagocytosis
IgG2b 25 μg FcγRIII > FcγRIV, C′ Erythrophagocytosis
IgG3 100 μg C′ Erythrophagocytosis
IgG1 500 μg FcγRIII Erythrophagocytosis
IgM 25 μg Agglutination Hemagglutination
aThe quantity of mAb required for inducing hematocrit values <40%
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were highly sensitive to antibody-induced complement-
dependent hemolysis in vitro [39].
It should be stressed that despite strong activation of
complement, as documented by C3 opsonization of RBCs
in mice injected with IgM anti-RBC mAb, no sign of CR-
mediated erythrophagocytosis by Kupffer cells was detect-
able. In fact, the pathogenic mechanism responsible for the
induction of anemia by IgM is a sequestration of RBCs due
to a massive hemagglutination in spleen and occasionally in
liver (Table 2), which likely interferes with the process of
CR-mediated erythrophagocytosis. It should also be em-
phasized that 4C8 IgM anti-RBC mAb is as pathogenic as
the 34-3C IgM variant, although its affinity is more than
1,000 times weaker than that of 34-3C [15]. This indicates
that the affinity of IgM anti-RBC autoantibodies is not of
primary importance for their pathogenic activity because its
pentameric form dramatically enhances the binding avidity
to autoantigens expressed on RBCs. Significantly, the
monomeric form of 34-3C IgM variant completely fails to
induce anemia, despite its high-affinity binding to circulat-
ing RBCs in vivo (manuscript in preparation). The lack of
pathogenicity of the monomeric form of IgM anti-RBC
mAb can be explained by its inability to induce hemagglu-
tination, by its poor activation of complement, and by the
absence of phagocytic receptors specific for IgM.
Differential contributions of FcγRI, FcγRIII,
and FcγRIV to IgG-subclass-dependent pathogenicity
of anti-RBC autoantibodies
It has been well established that activating FcγRs are
critically involved in the pathogenesis of various autoanti-
body- and IC-mediated inflammatory disorders [52, 62].
However, the respective contributions of the three different
activating FcγRs (FcγRI, FcγRIII, and FcγRIV) have not
yet been well defined, except for IgG1 IC-mediated
inflammation which is exclusively mediated by FcγRIII
[19, 20]. We have recently assessed the development of
mild or severe anemia by injecting low or high doses of
34-3C IgG2a or IgG2b mAb in mice deficient in FcγRI,
FcγRIII, and/or C3 to define respective contributions of
different FcγRs to the development of IgG2a- and IgG2b-
mediated autoimmune hemolytic anemia. We have ob-
served that the development of mild anemia induced by a
low dose of these mAb (25 μg) was completely prevented
in FcγRIII-deficient mice, whereas the injection of a high
dose (200 μg) still induced anemia in mice deficient in
FcγRI, FcγRIII, and C3 (manuscript in preparation). This
indicates not only a critical role for FcγRIII in the initiation
of autoimmune hemolytic anemia, but also a secondary role
for FcγRIV in the progression and development of severe
anemia (Table 2). The limited use of FcγRIV in vivo could
be due to competition with excessive amounts of unbound
monomeric IgG2a and IgG2b due to higher affinity of
FcγRIV for IgG2a and IgG2b compared with FcγRIII [47].
Thus, only higher densities of 34-3C mAb bound on RBCs
may efficiently compete with circulating monomeric IgG2a
and IgG2b for FcγRIV binding on phagocytes, while a low
density of 34-3C mAb on RBCs can still trigger FcγRIII-
dependent erythrophagocytosis because of the absence of
the competition. However, it should be stressed that
FcγRIV has been shown to play a remarkable role in the
development of autoimmune thrombocytopenia induced by
the IgG2a and IgG2b subclasses of an antiplatelet mAb [47]
and in the development of experimental nephrotoxic
glomerulonephritis [29]. This apparent discrepancy could
be explained by differential expression levels of FcγRIII
and FcγRIV on distinct immune effector cells such as
macrophages, Kupffer cells, mast cells, and mesangial cells
implicated in triggering IC-mediated inflammatory cascade.
Consequently, the respective contributions of both types of
FcγRs may be dramatically different, depending on the
experimental models studied. In contrast to FcγRIII and
FcγRIV, it is expected that the role of FcγRI is relatively
limited because of the competition with circulating,
unbound, monomeric IgG2a. Again, we cannot exclude
the possibility that increased avidity due to extensive
opsonization may result in a more efficient binding to
FcγRI and contribute to the development of autoimmune
hemolytic anemia. Notably, a significant contribution of
FcγRI to the development of different IgG2a IC-mediated
inflammatory lesions has been reported [4, 22]. Clearly,
further studies in mice deficient in different activating
FcγRs will provide a more definitive perspective of the
respective roles of individual FcγRs in the pathogenesis of
autoantibody- and IC-mediated immune disorders.
Murine phagocytic effector cells express an additional
low-affinity FcγR, FcγRIIB, which is a single α-chain
receptor, in which the cytoplasmic domain contains the
inhibitory ITIM (immunoreceptor tyrosine-based inhibition
motif) sequence [63]. Upon co-ligation of the inhibitory
FcγRIIB with activating FcγR or B-cell antigen receptor,
cellular activation is inhibited by the recruitment of an
inositol polyphosphate phosphatase, SHIP, which mediates
the inhibition of calcium flux. The importance of FcγRIIB
for the negative regulation of FcγRI-, FcγRIII-, and
FcγRIV-dependent effector functions in vivo has been
demonstrated by markedly enhanced anaphylactic and
inflammatory immune responses in FcγRIIB-deficient mice
[9, 45, 56, 63, 66]. However, we have shown that FcγRIIB
is unable to down-regulate activating FcγR-mediated
phagocytosis of RBCs opsonized with 105-2H IgG1 anti-
RBC mAb [56] or 34-3C IgG2a in vivo (unpublished data).
These results are in marked contrast with the substantial
inhibitory role of FcγRIIB against the development of
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immune thrombocytopenia induced by IgG2a and IgG2b
antiplatelet mAb [45, 54]. It remains to be determined
whether the development of thrombocytopenia following
injection of IgG antiplatelet autoantibodies is mediated not
only by FcγR-dependent phagocytosis but also by another
mechanism (release of cytotoxic agents by activated macro-
phages) and whether the latter may efficiently be counter-
regulated by the co-engagement of FcγRIIB.
More recent surface plasmon resonance analysis using
recombinant proteins of different classes of FcγR α-chains
revealed that the binding affinity of FcγRIII for IgG2a and
IgG2b subclasses is higher than that for IgG1, whereas the
binding affinity of FcγRIIB for IgG2a is lower than that for
IgG1 and IgG2b [45]. Notably, FcγRIV displays a
comparable affinity for IgG2a and IgG2b, but no affinity
for IgG1. These results, together with the fact that IgG2a is
the only subclass interacting with FcγRI, confirm that the
IgG2a subclass of autoantibodies is the most pathogenic
one since it most efficiently interacts with three activating
FcγRs (and complement), but less efficiently with inhibi-
tory FcγRIIB (Table 1).
Pathogenicity of IgG3 monoclonal autoantibodies
Analysis of a panel of murine mAb revealed that the IgG3
subclass has a unique physicochemical property, which
allows it to self-associate via Fc–Fc interactions and exhibit
cryoglobulin activity independently of their specificities
[1]. The self-associating property of the IgG3 subclass is
necessary, but not sufficient in itself to confer cryoglobulin
activity since not all monoclonal IgG3 proteins exhibit
cryoglobulin activity. MRL-Faslpr autoimmune mice defi-
cient in Fas apoptosis receptor spontaneously develop a
lupus-like syndrome characterized by unique immunopath-
ological manifestations such as arthritic-like lesions, necro-
tizing vascular lesions of the skin of ears and footpads, and
severe glomerulonephritis [2]. In parallel, they produce the
highest amounts of cryoglobulins among several lupus-
prone mice, including (NZB×NZW)F1 and BXSB mice [1].
Cryoglobulins from MRL-Faslpr mice are composed almost
exclusively of IgG of polyclonal origin, in which the IgG3
content is markedly enriched as compared with other IgG
subclasses.
Most significantly, a fraction of cryoprecipitating IgG3
monoclonal anti-IgG2a RF and anti-DNA autoantibodies
derived from lupus-prone mice are highly pathogenic,
generating glomerular and vascular lesions [5, 24, 34, 60].
For example, the implantation of hybridoma cells secreting
IgG3 anti-IgG2a RF derived from lupus-prone MRL-Faslpr
mice rapidly induced acute glomerulonephritis character-
ized by “wire-loop”-like glomerular lesions and cutaneous
leukocytoclastic vasculitis [5, 34]. The pathogenic potential
of IgG3 autoantibodies has been confirmed by the analysis
of Ig class switch variants of 6-19 anti-IgG2a RF mAb
[5, 17, 43]. Furthermore, we have observed that 6-19 IgG3
anti-IgG2a RF mAb induced the development of glomeru-
lar but not cutaneous vascular lesions in Ig-deficient mice
lacking the corresponding IgG2a autoantigens [26, 53].
Thus, both RF and cryoglobulin activities are required for
the development of skin vasculitis, whereas renal pathoge-
nicity is not dependent on the anti-IgG2a RF property.
However, studies with 6-19 transgenic mice clearly showed
that the nephritogenicity of the 6-19 RF mAb was
determined by a unique combination of 6-19 heavy and
light chains: 6-19 heavy-chain transgenic mice completely
failed to develop any glomerular lesions, in combination
with endogenous diverse light chains, despite the presence
of substantial amounts of cryoglobulins [30]. However, it
remains to be determined whether a cross-reactivity of the
6-19 RF mAb with glomerular antigen is a possible
mechanism for the nephritogenicity of the 6-19 RF mAb.
Polymorphonuclear neutrophils (PMN) are the principal
inflammatory cells in skin vascular lesions caused by the
6-19 RF mAb since no skin purpuric lesions developed in
mice depleted of PMN [18]. Strikingly, mice deficient in C3
still developed typical cutaneous vascular lesions [26].
Thus, complement activation does not play a major role in
the pathogenesis of PMN-dependent skin vascular lesions
induced by 6-19 IgG3 RF. In contrast, mice deficient in
FcγR were unable to develop skin vasculitis following the
implantation of 6-19 RF hybridoma cells, but were capable
of doing so after the transfer of wild-type FcγR-expressing
mast cells [68]. We speculate that the activation of mast
cells, through the interaction of FcγRIII with IgG2a-IgG3
IC, may result in the release of inflammatory mediators that
recruit and activate PMN, thereby generating leukocyto-
clastic vascular lesions. Further analysis with mice deficient
in tumor necrosis factor (TNF) has demonstrated that TNF
released from activated mast cells was one of the mediators
responsible for triggering leukocytoclastic vasculitis [68],
thus illustrating the clinical significance of TNF in IC-
mediated autoimmune vascular syndrome.
In a marked contrast to the pathogenetic mechanisms
responsible for cutaneous leukocytoclastic vascular lesions,
the development of glomerulonephritis induced by
6-19 IgG3 RF was not dependent on the activation of
FcγR-expressing cells [68]. The lack of any inhibition of
glomerular lesions in FcγR-deficient mice is consistent
with the fact that the development of these glomerular
lesions is independent of the formation of IgG3-IgG2a IC
[26, 53]. It has recently been reported that FcγR-mediated
inflammatory responses play an important role in the
pathogenesis of lupus nephritis occurring in (NZB×NZW)
F1, but not in MRL-Faslpr mice [8, 37]. Considering that
MRL-Faslpr mice spontaneously generate extremely large
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amounts of IgG3 cryoglobulins [1], these data suggest that
lupus nephritis occurring in MRL-Faslpr mice might be
more dependent on the production of IgG3 autoantibodies,
which fail to activate FcγR [3], and thus less dependent on
IC formation and FcγR. This is consistent with the
observation that the progression of lupus nephritis in
MRL-Faslpr mice was well correlated with the level of
circulating IgG3 autoantibodies [59, 61].
To better define the immunopathological consequences
associated with the chronic presence of pathogenic 6-19
autoantibodies in sera, as opposed to acute and rapid
elevation following implantation of 6-19 hybridoma, we
have recently established a transgenic mouse line express-
ing IgG3 6-19 RF mAb [30]. These transgenic mice
developed severe chronic glomerulonephritis, which were
highly heterogeneous, as observed in lupus-prone mice,
within 8–10 months of age. In addition, about one third of
aged transgenic mice developed necrotizing arteritis in
small- and medium-sized arteries of the kidney and skeletal
muscle, characterized by fibrinoid necrosis and PMN
infiltration in association with a perivascular mononuclear
cell infiltration. These changes contrasted markedly with
the renal and vascular lesions resulting from the rapid
induction of high serum levels of 6-19 RF mAb, induced
within 8–10 days after implantation of 6-19 hybridoma in
normal mice. In the latter situation, mice developed less
heterogeneous glomerular lesions, consisting of massive
endothelial wire-loop and intracapillary deposits, as well as
a cutaneous leukocytoclastic vasculitis in arterioles [5, 34].
These results demonstrate that a single autoantibody can
induce remarkably different types of glomerular and
vascular lesions, depending on its production levels and
kinetics.
The demonstration of the pathogenic potential of
monoclonal autoantibodies of the IgG3 subclass with
cryoglobulin activity is significant because cryoglobulins
have long been suggested to be a potential source of tissue
injuries in SLE, rheumatoid arthritis, and related autoim-
mune diseases [6]. Clearly, the presence of cryoprecipitable
autoantibodies should be reassessed in relation to clinical
manifestations to determine whether this subset of autoanti-
bodies is a useful and predictive marker of human
rheumatic diseases.
Inhibitory effect of sialylation on the pathogenicity
of IgG autoantibodies
The CH2 domain of each IgG heavy chain bears a
biantennary-complex-type oligosaccharide chain linked to
asparagines at position 297, which has been thought to
stabilize the IgG molecule and to contribute to Fc-
associated effector functions. Most of these oligosaccharide
side chains are nonsialylated and end with either two
N-acetylglucosamines, one N-acetylglucosamine and one
galactose, or two galactose residues (Fig. 1). However, a
significant fraction of galactosylated oligosaccharide chains
bear one or two terminal sialic acids and hence become
more negatively charged. Since the level of galactosylation
is highly heterogeneous and substantially diminished in
patients with rheumatoid arthritis and in lupus-prone MRL-
Faslpr mice [40, 50], differences in the structure of
carbohydrate side chains may have an important role in
modulating the pathogenicity of autoantibodies. Since it has
been shown that a mutation at position 265 (from aspartic
acid to alanine; D265A) leads to a change in the pattern of
IgG galactosylation and sialylation [35], we introduced this
D265A mutation into the 34-3C IgG2a heavy-chain gene.
The activation of complement and interaction with FcγR on
phagocytes were dramatically reduced as a result of the
introduction of this mutation, and IgG2a D265A mutant
became poorly pathogenic (manuscript in preparation).
Surface plasmon resonance analysis confirmed that the
IgG2a D265A mutant failed to interact with C1q and with
all four types of FcγR.
The structural analysis of oligosaccharide side chains
isolated from the 34-3C IgG2a D265A mutant has indeed
shown increased galactosylation and sialylation as com-
Man β 1 4GlcNAc β 1 4GlcNAc6
3
±Fuc α 1
±Sia α 2 6Gal β 1 4GlcNAc β 1 2Man α 1
±
±Sia α 2 6Gal  β1 4GlcNAc β 1 2Man α 1
±
6
Fig. 1 Structure of authentic biantennary-complex-type oligosaccha-
ride chains of IgG. The extent of the terminal sialylation and
galactosylation of oligosaccharide side chains is highly variable
(indicated as ±), and more than 95% of oligosaccharides are
fucosylated. Gal galactose, GlcNAc N-acetylglucosamine, Man man-
nose, Fuc fucose
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pared with its wild-type counterpart. It has been speculated
that aspartic acid at position 265 contacts the primary
N-acetylglucosamine of oligosaccharide side chains and
that this interaction may lead to the sequestration of the
nascent oligosaccharide from glycosylation enzymes [35].
Thus, the reduced interaction of alanine with N-acetylglu-
cosamine in the D265A mutant could increase the acces-
sibility of the nascent oligosaccharide to glycosylation
enzymes, thereby increasing galactosylation and sialylation.
At present, it is not clear whether the loss of effector
functions of the D265A mutant is due to an increased
galactosylation and/or an increased sialylation. A previous
publication on agalactosylated IgG from patients with
rheumatoid arthritis has claimed that exposure of N-
acetylgucosamine by agalactosylated IgG could result in
an interaction with mannose-binding lectin, thereby acti-
vating complement cascade [36]. However, our analysis of
glycosylation of 34-3C IgG subclass switch variants
showed that the IgG1 variant carries an increased content
of agalactosylated glycoforms as compared with other IgG
subclasses (unpublished data), but is unable to activate
complement. Thus, this result rather argues against the idea
that increased complement activation by agalactosylated
IgG is mediated through the interaction of N-acetylglucos-
amine with mannose-binding lectin.
In addition to the change in galactosylation, we also
noted an increased sialylation of the IgG1 class switch
variant, the extent of which was comparable with that of
IgG2a D265A mutant. These results raise the attractive
hypothesis that poor IgG effector functions of the IgG1
subclass may be related to an increased sialylation. An
increased sialylation may result in conformational changes
of the Fc structure, which may be responsible for the lack
of complement activation and for relatively poor interaction
with activating FcγR. Alternatively, increases in negative
charges due to sialylation may interfere with the interaction
of IgG1 with C1q and FcγR. Indeed, charged amino acid
residues present at positions 318, 320, and 322 (glutamic
acid, lysine, and lysine, respectively), which are also
present in IgG1, are involved in C1q binding [11]. In
addition, the introduction of negatively charged glutamic
acid into the FcγRI-binding motif at positions 234–238 is
known to result in a complete loss of FcγRI interaction of
IgG2a [12].
In view of the implication in IgG3 cryoglobulin activity
of more positively charged amino acid residues at positions
6 and 23 of the heavy-chain variable (VH) regions [32, 49],
we have recently explored the inhibitory effect of terminal
sialic acids on the cryogenic activity of IgG3 mAb.
Comparative oligosaccharide structural analysis of different
cryogenic and noncryogenic IgG3 mAb showed an inverse
correlation between the extent of sialylation and cryogenic
activity [31]. The inhibitory role of sialylation was further
confirmed by the demonstration of enrichment of less and
more sialylated IgG3 in cryoprecipitated and noncryopre-
cipitated fractions, respectively, separated from different
cryogenic IgG3 mAb. Interestingly, one of the mAb, 9-106,
which is supposed to be cryogenic because of the presence
of more positively charged amino acid residues at positions
6 and 23 of the VH region, failed to display cryoglobulin
activity, and its content of sialic acids was abnormally
elevated due to the presence of additional oligosaccharide
chains in its VH region [31]. Furthermore, we have recently
observed that the introduction of a mutation in the CH2
domain or in a potential glycosylation site in the VH region
of the cryogenic 6-19 IgG3 mAb resulted in an increased
sialylation and in the loss of its cryoglobulin activity
(unpublished data). Taken together, these results suggest
that the content of negatively charged sialic acids in
oligosaccharide side chains is a critical factor in determin-
ing IgG3 cryoglobulin activity.
Our demonstration of poor pathogenic activity of more
sialylated IgG autoantibodies indicates that the level of IgG
sialylation could be an important factor in determining the
pathogenic potential of autoantibodies. Furthermore, this
would be in line with the increased levels of agalactosylated
(i.e., asialylated) IgG in patients with rheumatoid arthritis
and in lupus-prone MRL-Faslpr mice [40, 50]. The level of
galactosylation and sialylation is likely to be regulated by
one of the six isoforms of β-1,4-galactosyltransferases and
by α2,6-sialyltransferase, respectively. Dysregulated ex-
pression of β-1,4-galactosyltransferase and α2,6-sialyl-
transferase could be a significant genetic factor
predisposing to the development of autoantibody-mediated
tissue lesions. Notably, recognition of sialic acid by factor
H in the alternative complement pathway is used to dampen
complement activation through the inactivation of C3b
deposited on self-membranes [13]. Furthermore, α2,
6-linked sialic acid, which is a common structure on
asparagine-linked glycans and is abundantly expressed on
the surface of many cells, can be recognized by CD22
expressed on B cells. Since CD22 is a negative regulator of
B-cell activation, this could be a mechanism to prevent
activation of potentially autoreactive B cells [33]. All these
data are consistent with the idea that sialic acids play a
protective role against self-destruction in higher organisms.
Critical role of the Th1 subset for the development
of SLE
The assessment of the pathogenic potential of different
monoclonal autoantibodies derived from lupus-prone mice
revealed that the IgG2a subclass of anti-RBC autoanti-
bodies is the most pathogenic because of the strongest Fc-
associated effector functions. Moreover, the IgG3 subclass
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of autoantibodies has a unique pathogenic potential to
induce development of glomerulonephritis and vasculitis
because of the formation of self-associating complexes and
cryoglobulins. Interferon (IFN)-γ, the prototype Th1
cytokine, promotes the production of IgG2a and IgG3,
and therefore, Th1-type autoimmune responses may be
critically important in autoantibody-mediated autoimmune
diseases, such as SLE. In contrast, interleukin (IL)-4, the
Th2 cytokine, promotes the switching to IgG1, which is the
least pathogenic IgG subclass.
Several findings have underscored the importance of
Th1 autoimmune responses in the progression of murine
lupus nephritis. First, an accelerated development of SLE
was observed in MRL-Faslpr and MRL.Yaa mice (Yaa is an
as-yet-unidentified mutation able to accelerate the develop-
ment of SLE [27]). In these mice, it has been shown that the
progression of disease was correlated with an enhanced
expression of IFN-γ vs IL-4 mRNA in CD4+ T cells and an
increase in spontaneous production of IgG2a and IgG3 vs
IgG1 anti-DNA autoantibodies [61]. Second, the develop-
ment of lupus nephritis in lupus-prone (NZW×C57BL/6)F1
males bearing the Yaa mutation was almost completely
prevented by transgenic expression of IL-4 in B cells; the
protected mice had a lack of IgG3, a decrease in IgG2a, and
an increase in IgG1 anti-DNA autoantibody production
[55]. The protective effect of the IL-4 transgene has also
been confirmed in the classical (NZB×NZW)F1 mouse
model of SLE (unpublished data). Third, MRL-Faslpr mice
deficient in the T-box transcription factor T-bet, which
plays a critical role in Th1 lineage commitment, were
protected from lupus nephritis in association with a
decrease in serum levels of IgG2a and IgG3 vs an increase
in IgG1 [51].
These results provide evidence for the hypothesis that
the Th1 responses determine the development and progres-
sion of SLE by promoting the switch towards more
pathogenic IgG subclasses of autoantibodies. However, this
does not necessarily exclude an active role of Th2
responses in SLE since Th2 cytokines such as IL-5, IL-6,
and IL-10 have been suggested to be involved in the
induction of autoimmune manifestations in SLE [14, 23,
48]. These effects may be related to the ability of Th2
cytokines to augment overall production of pathogenic
autoantibodies by promoting the terminal differentiation of
activated B cells to plasma cells. Clearly, further under-
standing of the respective roles of Th1 and Th2 in SLE
would help establish new strategies for the development of
more specific treatments of SLE and related autoimmune
diseases.
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